Shenzhou Cell announced that recently, the holding subsidiary Shenzhou Cell Engineering Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of SCT640C injection, a product independently developed by the company, to carry out clinical trials for human rheumatoid arthritis indications.

Shenzhou Cell announced that recently, the holding subsidiary Shenzhou Cell Engineering Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of SCT640C injection, a product independently developed by the company, to carry out clinical trials for human rheumatoid arthritis indications.